![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
AVM0703 is small molecule immunomodulatory drug enrolling Phase 2 trials in US in relapsed/refractory Non-Hodgkin's Lymphoma (NHL) which began enrollment Q3 2023 (partially funded by NCI Ph II FastTrak grant 1R44CA272096).
Lead Product(s): Dexamethasone Sodium Phosphate
Therapeutic Area: Oncology Product Name: AVM0703
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2023
Details:
AVM0703 (Dexamethasone sodium phosphate) is a small molecule which triggers the production and release of endogenous bispecific gamma delta TCR+ invariant TCR+ Natural Killer T-like cells (AVM-NKT).
Lead Product(s): Dexamethasone Sodium Phosphate
Therapeutic Area: Oncology Product Name: AVM0703
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Cancer Institute
Deal Size: $2.0 million Upfront Cash: Undisclosed
Deal Type: Funding June 14, 2022
Details:
AVM0703 (dexamethasone) led to, complete response in 27% of immune-resistant mouse A20 tumors as monotherapy and complete response in 60% when combined with 2 doses of cyclophosphamide/fludarabine (CyFlu).
Lead Product(s): Dexamethasone Sodium Phosphate
Therapeutic Area: Oncology Product Name: AVM0703
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2022
Details:
AVM0703 is a small molecule which triggers the production and release of endogenous bispecific gamma delta TCR+ and invariant TCR+ Natural Killer T-like cells (AVM-NKT).
Lead Product(s): Dexamethasone
Therapeutic Area: Oncology Product Name: AVM0703
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 19, 2022
Details:
T1D is an autoimmune disease that destroys beta cells, the insulin-making cells in the pancreas. This award provides an endorsement of AVM0703’s potential in two distinct and crucial therapeutic areas, diabetes and cancer.
Lead Product(s): Dexamethasone
Therapeutic Area: Endocrinology Product Name: AVM0703
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Institute of Diabetes and Digestive Kidney Disease
Deal Size: $1.6 million Upfront Cash: Undisclosed
Deal Type: Funding April 05, 2022
Details:
This second study will evaluate AVM0703 in two different ARDS patient populations: one with COVID-19-mediated moderate to severe ARDS and the other with Influenza-mediated severe ARDS.
Lead Product(s): Dexamethasone Sodium Phosphate
Therapeutic Area: Infections and Infectious Diseases Product Name: AVM0703
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 16, 2020
Details:
AVM Biotechnology has been awarded a National Cancer Institute Small Business Innovation Research Grant from the NIH to study the use of AVM0703 as a preconditioning agent to allow safe and efficient delivery of therapeutic immune cells for cancer treatment.
Lead Product(s): Dexamethasone Sodium Phosphate,Hydrocortisone,Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 11, 2020
Details:
AVM Biotechnology received clinical trial approval for AVM0703. Unlike chemotherapy and radiation, AVM0703 spares platelets and red blood cells, limiting the need for transfusions.
Lead Product(s): Dexamethasone Sodium Phosphate
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 14, 2020